LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD)

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Silva, Amanda Karolina Soares E ^a   De Torres, Dilênia Oliveira Cipriano ^b   Gomes, Fabiana Oliveira Dos Santos ^a   Silva, Bruna Dos Santos ^a   Ribeiro, Edlene Lima ^a   Oliveira, Amanda Costa ^a   Santos, Laise Aline Martins Dos ^a   De Lima, Maria Do Carmo Alves ^c   Pitta, Ivan Da Rocha ^c   Peixoto, Christina Alves ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^c FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 CHLORO BENZYLIDENE) 3 (4 METHYLBENZYL)THIAZOLIDINE 2,4 DIONE; ABC TRANSPORTER A1; CD220 ANTIGEN; COLLAGEN; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLITAZONE DERIVATIVE; I KAPPA B ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; LYMPHOCYTE ANTIGEN; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN F4 80; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5-(4-CHLOROBENZYLIDENE)-3-(4-METHYLBENZYL)THIAZOLIDINE-2,4-DIONE; EMR4 PROTEIN, MOUSE; EPIDERMAL GROWTH FACTOR; I KAPPA B; I KAPPA B KINASE ALPHA; LOW DENSITY LIPOPROTEIN RECEPTOR; NFKBIA PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; INSULIN RESISTANCE; LIPID DIET; LIPID STORAGE; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; BLOOD; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; GENETICS; INFLAMMATION; KNOCKOUT MOUSE; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY;

ANIMALIA; MURINAE; MUS;

ANIMALS; CYCLOOXYGENASE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; I-KAPPA B PROTEINS; INFLAMMATION; INTERLEUKIN-6; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPAB INHIBITOR ALPHA; NITRIC OXIDE SYNTHASE TYPE II; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, LDL; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 84928811290     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123787     Document Type: Article

References (79)

1. De Alwis NM, Day CP. (2008) Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatology 48: 104-112.
2. Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. (2011) Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes Obes Metab 13: 692-702. doi: 10.1111/j.1463-1326.2011.01403.x PMID: 21449949
3. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, et al. (2005) Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 288: 462-468.
4. Tilg H, Moschen AR. (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52: 1836-1846. doi: 10.1002/hep.24001 PMID: 21038418
5. Day CP, James OF. (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845. PMID: 9547102
6. Keaney JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. (2003) Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23: 434-439. PMID: 12615693
7. Shoelson SE, Lee J, Goldfine AB. (2006) Inflammation and insulin resistance. J. Clin. Invest 116: 1793-1801. PMID: 16823477
8. Muriel P. (2009). NF-kB in liver diseases: a target for drug therapy. J. Appl. Toxicol 29: 91-100. doi: 10.1002/jat.1393 PMID: 18937212
9. Lawrence T. (2009). The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol 1: 1-18.
10. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. (2005). Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF kappaB. Nat. Med 11: 183-190. PMID: 15685173
11. Karin M., Delhase M. (2000). The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin. Immunol. 12: 85-98. PMID: 10723801
12. Hayden MS, Ghosh S. (2004). Signaling to NF-kappaB. Genes Dev 18: 2195-2224. PMID: 15371334
13. Baeuerle PA, Baltimore D. (1988). I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science 242: 540-546. PMID: 3140380
14. Ghosh S, Baltimore D. (1990). Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature 344: 678-682. PMID: 2157987
15. Girard J. Mechanisms of action of thiazolidinediones. (2001) Diabetes Metab 27: 271-8. PMID: 11452221
16. Yki-Jarvinen H. (2004) Thiazolidinediones. N Engl J Med 351:1106-18. PMID: 15356308
17. Watkins PB. Insight into hepatotoxicity: The troglitazone experience. (2005) Hepatology 41:229-30. PMID: 15657920
18. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? (2001) Drug Saf 24: 873-88. PMID: 11735645
19. Lutchman G, Modi A, Kleiner DE, Promrat K, Heller T, Grany M, et al. (2007) The effects of discontinuing pioglitazone in pateints with nonalcoholic steatohepatitis. Hepatology 46:424-9. PMID: 17559148
20. Nissen SE, Wolski K. (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 2457-71. PMID: 17517853
21. Ratziu V, Giral P, Jacqueminet S, Charlotte F, Hartemann-Heurtier A, Serfaty L, et al. (2008) Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135:100-10. doi: 10.1053/j.gastro.2008.03.078 PMID: 18503774
22. Schalm SW. (1997) The diagnosis of cirrhosis: clinical relevance and methodology. J Hepatol. 27(6):1118-9. PMID: 9453441
23. Iredale JP. (2003) Cirrhosis: new research provides a basis for rational and targeted treatments. BMJ 19:143-7.
24. Silva AKS, Torres DOC, Rocha SWS, Gomes FOS, Silva BS, Donato MA, et al. (2013) Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice LDLR(-/-). Cardiovasc Pathol 22(1): 81-90. doi: 10.1016/j.carpath.2012.05.006 PMID: 22795892
25. Leite LFC, Mourão RHV, Lima MC, Galdino SL, Hernandes MZ, Neves FAR, et al. (2007). Synthesis, biological evaluation and molecular modeling studies of arylidene-thiazolidinediones with potential hypoglycemic and hypolipidemic activities. Eur J Med Chem. 42: 1263-1271. PMID: 17448573
26. Mourão RH, Silva TG, Soares AL, Vieira ES, Santos JN, Lima MC, et al. (2005) Synthesis and Biological Activity of Novel Acridinylidene and Benzylidene thiazolidinediones. Eur J Med Chemistry 40: 1129-1133. PMID: 16040159
27. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. et al. (2000) Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Investig 106: 523-531. PMID: 10953027
28. Game BA, He L, Jarido V, Nareika A, Jaffa AA, Lopes-Virella MF, et al. (2007) Pioglitazone inhibits connective tissue growth factor expression in advanced atherosclerotic plaques in low-density lipoprotein receptor-deficient mice. Atherosclerosis 192: 85-91. PMID: 16901490
29. Gupte AA, Liu JZ, Ren Y, Minze LJ, Wiles JR, Collins AR, et al. (2010) Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice. Hepatology. 52(6): 2001-11. doi: 10.1002/hep.23941 PMID: 20938947
30. Bradford MA. (1970) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 240-54.
31. Montes GS, Junqueira LCU. (1988) Histochemical localization of collagen and of proteoglycans in tissues. CRC press. 41-72.
32. Sehgal PB, Grieninger G, Tosato G (eds) (1989) Regulation of the acute phase and immune responses: interleukin-6. Ann New York Acad Sci 557:1-583.
33. Wilkins T, Tadkod A, Hepburn I, Schade RR. (2013) Nonalcoholic fatty liver disease: diagnosis and management. Am Fam Physician 88(1):35-42. PMID: 23939604
34. Collins AR. Meehan WP, Kintscher U, Jackson S, Wakino S, Noh G, et al. (2001). Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptordeficient mice. Arterioscler Throm Vasc Biol. 21: 365-371. PMID: 11231915
35. Napoli C, Nigris F, Welch JS, Calara FB, Stuart RO, Glass CK, et al. (2002) Maternal hypercholesterolemia during pregnancy promotes early atherogenesis in LDL receptor-deficient mice and alters aortic gene expression determined by microarray. Circulation 105: 1360-7. PMID: 11901049
36. Ozasa H. Ayaori M, Iizuka M, Terao Y, Uto-Kondo H, Yakushiji E, et al. (2011) Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPAR-/LXR-pathway: Findings from in vitro and ex vivo studies. Atherosclerosis. 219: 141-150. doi: 10.1016/j.atherosclerosis.2011.07.113 PMID: 21862012
37. Varas-Lorenzo C, Margulis AV, Pladevall M, Riera-Guardia N, Calingaert B, Hazell L, et al. (2014) The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies. BMC Cardiovasc Disord 14(1): 1-17. doi: 10.1186/1471-2261-14-1 PMID: 24400643
38. Camp HS. (2003) Thiazolidinediones in diabetes: current status and future outlook. Curr Opin Investig Drugs 4:406-11. PMID: 12808879
39. Yang LY, Kuksis A, Myher JJ, Steiner G. (1995) Origin of triacylglycerol moiety of plasma very low density lipoproteins in the rat: structural studies. Journal of Lipid Research 36: 125-136. PMID: 7706937
40. Yamaguchi L, Yang L, McCall S, Huang J, Yu XX, Pandey SK, et al. (2007). Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45 (6): 1366-1374. PMID: 17476695
41. Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, et al. (2000) Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J. Clin. Invest. 106: 1221-1228. PMID: 11086023
42. Memon RA, Tecott LH, Nonogaki K, Beigneux A, Moser AH, Grunfeld C, et al. (2000). Up-regulation of peroxisome proliferatoractivated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology 141: 4021-4031. PMID: 11089532
43. Bedoucha M, Atzpodien E, Boelsterli UA. (2001) Diabetic KKAy mice exhibit increased hepatic PPAR-gamma1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J. Hepatol 35:17-23. PMID: 11495036
44. Morán-salvador E, López-Parra M, García-Alonso V, Titos E, Martínez-Clemente M, González-Périz A, et al. (2011) Role for PPARã in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J 25: 2538-2550. doi: 10.1096/fj.10-173716 PMID: 21507897
45. Zhang W, Xu YZ, Liu B, Wu R, Yang YY, Xiao XQ, et al. (2014) Pioglitazone Upregulates Angiotensin Converting Enzyme 2 Expression in Insulin-Sensitive Tissues in Rats with High-Fat Diet-Induced Nonalcoholic Steatohepatitis. Hindawi Publishing Corporation. the Scientific World Journal. Article ID 603409.
46. Wang HN, Wang YR, Liu GQ, Liu Z, Wu PX, Wei XL, et al. (2008) Inhibition of hepatic interleukin-18 production by rosiglitazone in a rat model of nonalcoholic fatty liver disease. World J Gastroenterol 14(47): 7240-7246. PMID: 19084941
47. Ciupińska-Kajor M, Hartleb M, Kajor M, Kukla M, Wyleżoł M, Lange D, et al. (2013) Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int. v 7 (1): 233-240. PMID: 23519653
48. Nasir GA, Mohsin S, Khan M, Shams S, Ali G, Khan SN, et al. (2013) Mesenchymal stem cells and Interleukin-6 attenuate liver fibrosis in mice. Journal of Translational Medicine 11: 1-9. doi: 10.1186/1479-5876-11-1 PMID: 23281771
49. Yudkin JS. Kumari M, Humphries SE, Mohamed-Ali V. (2000) Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 148: 209-214. PMID: 10657556
50. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. (2005) Local and systemic insulin resitance resulting from hepatic activation of IKK beta and NF-KappaB. Nat Med 11: 183-190. PMID: 15685173
51. Kugelmas M. Hill DB, Vivian B, Marsano L, McClain CJ. (2003) Cytokines and NASH: a pilot study of the effects of lifestyle modifications and vitamin E. Hepatology 38: 413-419. PMID: 12883485
52. Haukeland JW. Damås JK, Konopski Z, Løberg EM, Haaland T, Goverud I, et al. (2006) Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 44: 1167-1174. PMID: 16618517
53. Mas E. Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T, et al. (2009) IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One 4: 7929.
54. Esterson YB. Zhang K, Koppaka S, Kehlenbrink S, Kishore P, Raghavan P, et al. (2013) Insulin Sensitizing and Anti-Inflammatory Effects of Thiazolidinediones Are Heightened in Obese Patients. Journal of Investigative Medicine. 61(8): 1152-1160. doi: 10.231/JIM.0000000000000017 PMID: 24141239
55. Mohapatra J. Sharma M, Singh S, Chatterjee A, Swain P, Balaraman R, et al. (2009) Subtherapeutic dose of pioglitazone reduces expression of inflammatory adipokines in db/db mice. Pharmacology 84(4):203-10. doi: 10.1159/000235996 PMID: 19738399
56. Yoneda M. Hotta K, Nozaki Y, Endo H, TomenoW, Watanabe S, et al. (2009) Influence of inducible nitric oxide synthase polymorphisms in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res 39: 963-971. doi: 10.1111/j.1872-034X.2009.00539.x PMID: 19624767
57. Salamone F, Galvano F, Cappello F, Mangiameli A, Barbagallo I, Li Volti G, et al. (2012) Silibinin modulates lipid homeostasis and inhibits nuclear factor kappa B activation in experimental nonalcoholic steatohepatitis. Res transl. 159 (6): 477-86. doi: 10.1016/j.trsl.2011.12.003 PMID: 22633099
58. Tian F. Zhang YJ, Li Y, Xie Y. (2014) Celecoxib ameliorates non-alcoholic steatohepatitis in type 2 diabetic rats via suppression of the non-canonical wnt signaling pathway expression. Plos one 9(1): e83819. doi: 10.1371/journal.pone.0083819 PMID: 24404139
59. Yu J. Ip E, Dela Peña A, Hou JY, Sesha J, Pera N, et al. (2006) COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology 43: 826-36. PMID: 16557554
60. Stienstra R. Saudale F, Duval C, Keshtkar S, Groener JE, van Rooijen N, et al. (2010) Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxime proliferator activated receptor aplha activity. Hepatology. 51(2): 511-22. doi: 10.1002/hep.23337 PMID: 20054868
61. Su GL. (2002). Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation. Am J Physiol Gastrointest Liver Physiol 283: G256-G265. PMID: 12121871
62. Rivera CA. Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M, et al. (2007) Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol. 47: 571-579. PMID: 17644211
63. Larter CZ, Yeh MM, Van Rooyen D, Brooling J, Ghatora K, Farrell GC, et al. (2012). Peroxisome proliferator-activated receptor-a agonist, Wy 14 643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 27 341-350 doi: 10.1111/j.1440-1746.2011.06939.x PMID: 21929649
64. Gonzalez FJ, Shah YM. (2008). PPARalpha: mechanism of species differences and hepatocarcinogenesis of peroxisome proliferators. Toxicology 246: 2-8. PMID: 18006136
65. Lalloyer F, Wouters K, Baron M, Caron S, Vallez E, Vanhoutte J, et al. (2011) Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in micePeroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in micePeroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice. Arterioscler Thromb Vasc Biol. 31(7): 1573-1579. doi: 10.1161/ATVBAHA.110.220525 PMID: 21474829
66. Kallwitz ER., MClachlan A, Cotler SJ. (2008). Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 14(1): 22-28. PMID: 18176957
67. Morán-salvador E, López-Parra M, García-Alonso V, Titos E, Martínez-Clemente M, González-Périz A, et al. (2011). Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts. FASEB J, 25: 2538-2550. doi: 10.1096/fj.10-173716 PMID: 21507897
68. Li Z, Nabel GJ. (1997). A new member of the I kappaB protein family, I kappaB epsilon, inhibits RelA (p65)-mediated NF-kappaB transcription. Mol Cell Biol. 17(10): 6184-90. PMID: 9315679
69. Tak PP, Firestein GS. (2001) NF-kappaB: um papel chave em doenças inflamatórias. J Clin Invest. 107 (1): 7-11. PMID: 11134171
70. Thomas D Gilmore. (1999) The Rel/NF-kB signal transduction pathway: introduction. Oncogene 18: 6842-6844. PMID: 10602459
71. Groszmann RJ, Wiest R. (2002) The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 35: 478-491. PMID: 11826425
72. Langer DA, Das A, Semela D, Kang-Decker N, Hendrickson H, Bronk SF. et al. (2008) Nitric oxide promotes caspase-independent hepatic stellate cell apoptosis through the generation of reactive oxygen species. Hepatology 47: 1983-1993. doi: 10.1002/hep.22285 PMID: 18459124
73. Matthews JR, Botting CH, Panico M, Morris HR, Hay RT, (1996). Inhibition of NF-kappaB DNA binding by nitric oxide. Nucleic Acids Res. 24: 2236-2242. PMID: 8710491
74. Grumbach IM, Chen W, Mertens SA, Harrison DG. (2005) A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J Mol Cell Cardiol. 39: 595-603. PMID: 16099468
75. Cheung O, Sanyal AJ. (2010). Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 26: 202-208. doi: 10.1097/MOG.0b013e328337b0c4 PMID: 20168226
76. Savage DB, Semple RK. (2010) Recent insights into fatty liver, metabolic dyslipidaemia and their links to insulin resistance. Curr Opin Lipidol 21: 329-336. doi: 10.1097/MOL.0b013e32833b7782 PMID: 20581678
77. Hotamisligil G.S. (2006) Inflammation and metabolic disorders. Nature. v 444: p 860-867. PMID: 17167474
78. Bochem AE, van Wijk DF, Holleboom AG, Duivenvoorden R, Motazacker MM, Dallinga-Thie GM, et al. (2013) ABCA1 mutation carriers with low-density lipoprotein cholesterol are characterized by a greater atherosclerotic burden. Eur Heart J. 34 (4): 286 91. doi: 10.1093/eurheartj/ehs376 PMID: 23136402
79. Liu W, Qin L, Yu H, Lv F, Wang Y. (2014) ApoA-1 and ABCA1 expression alleviates lipid accumulation in hepatocytes. J Gastroenterol Hepatol. 29(3): 614-22. doi: 10.1111/jgh.12430 PMID: 24219083